Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Post by 0buylowsellhighon Aug 31, 2015 10:34am
60 Views
Post# 24064850

Trading

TradingI am sure I am not the first to state this but I find that the best trade sometimes is no trade at all. One needs to judge fundamentals with technical and more. On the latter, knowing who is running the company is just as important as its products. Overall the market is a bear. Technically CPH is in dog territory. The management team is segregated in sales and the top down is suffering. I have my capital elsewhere at the moment but shorting is getting thin as it approaches my fair value of $5. Breaching that level will technically send CPH down to $2.80. This downfall can only turnaround with the next quarterly report. CPH has had only bad news over the past seven qtrs. Hold or short. Buying at this time is not in my cards. HAPPY$$$HUNTING!!!
Bullboard Posts